Cohen Milstein Seeks Investors Willing to Lead Zenas BioPharma (ZBIO) Securities Fraud Class Action

ZBIO Shares Tumble to Nearly 50% Post-IPO Stock Price

/EIN News/ -- WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who bought shares in the company’s September 2024 IPO may be eligible to participate in and lead a class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC, a nationally recognized investor rights law firm, is actively investigating claims and encouraging shareholders with significant losses to reach out now.

[Click here for information about joining the class action]

If you’d like to discuss this matter or your rights before signing up, please contact Molly J. Bowen, a partner at Cohen Milstein, at (202) 408-4600 or mbowen@cohenmilstein.com.

Why This Matters: The lawsuit alleges that Zenas BioPharma misled the investing public about its financial stability at the time of its IPO. Zenas BioPharma claimed it had sufficient cash on hand and expected proceeds to fund operations for at least 24 months. However, less than two months later, Zenas BioPharma disclosed in its quarterly filing that it could only sustain operations for 12 months. This stark revision undermined investor confidence, leading ZBIO shares to tumble to $8.72 by April 15, 2025—down nearly 49% from the IPO price of $17.00.

What Investors Need to Know: A class action lawsuit was filed on April 16, 2025, in the U.S. District Court for the District of Massachusetts. The complaint names Zenas BioPharma, key officers and directors, and several underwriters as defendants, citing violations of the Securities Act of 1933.

Investors who purchased shares in Zenas BioPharma’s IPO and suffered financial harm have until June 16, 2025, to seek appointment as lead plaintiff. Acting as lead plaintiff is optional and does not affect eligibility to recover losses.

ABOUT COHEN MILSTEIN: With over 100 attorneys across eight offices, Cohen Milstein is one of the nation’s premier plaintiffs’ law firms, known for securing significant recoveries in complex securities fraud cases. The firm recently recovered over $1 billion for investors as co-lead counsel in In re Wells Fargo & Company Securities Litigation. Recognized by The National Law Journal, Law360, Chambers USA, and The Legal 500, Cohen Milstein continues to set the standard for investor advocacy. Visit www.cohenmilstein.com to learn more.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:
Molly Bowen, Esq.
Licensed in DC, Florida, and Ohio
Cohen Milstein Sellers & Toll PLLC
1100 New York Avenue, N.W., Fifth Floor
Washington, D.C. 20005
Phone: (888) 240-0775 or (202) 408-4600
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com